BOTOX® for the Treatment of Platysma Prominence

* Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period * A female participant is eligible to participate if she is not pregnant (has a negative urine pregnancy result prior to randomization), not breastfeeding, and at least one of the following conditions applies: 1. Not a woman of childbearing potential (WOCBP) OR 2. A WOCBP who agrees to follow the studies contraceptive guidance during the treatment and follow-up period through study exit. * Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this study's protocol

* Any medical condition that may put the participant at increased medical risk with exposure to BOTOX®, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function * Participant has an anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention) * Anticipated need for surgery or overnight hospitalization during the study * Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study * Females who are pregnant, nursing, or planning a pregnancy during the study * Known immunization or hypersensitivity to any botulinum toxin serotype * History of alcohol or drug abuse within 12 months of the study * Participant has tattoos, jewelry, or clothing that cannot be removed, and that obscure the neck